METiS TechBio (剂泰科技)
Category: AI in Biotech / Drug Discovery
AI-driven nanomaterial and drug delivery platform company that went public on HKEX as the world's first AI drug delivery stock METiS TechBio (剂泰科技) was founded in 2020. The company is led by Dr. Chris Lai (赖才达). Based in Beijing, China. Team size: 201-500. Total funding raised: $315M. Latest round: IPO. Key investors include CICC Capital; HongShan (红杉中国); PICC Capital; China Life Private Equity; 5Y Capital (五源资本); Frees Fund (峰瑞资本); Lightspeed China (光速光合); Sourcode Capital (源码资本); CMB International; Monolith; Yayi Capital; Beijing Medical and Health Industry Investment Fund; Daxing Industrial Investment Fund; BlackRock (cornerstone); UBS AM Singapore; Mirae Asset; ORIX; Deerfield; RTW; Lake Bleu Capital (清池资本); Walden International (华登国际); Hillhouse (高瓴); IDG Capital.
- Founded
- 2020
- Headquarters
- Beijing, China
- Team size
- 201-500
- Total funding
- $315M
Value proposition
Using AI to design and optimize nanoscale drug delivery systems (LNPs, formulations) to dramatically accelerate drug development timelines and enable targeted delivery to specific organs and tissues
Products and solutions
NanoForge (global first AI nanodelivery platform); AiLNP (AI Nano Delivery System Design Platform); AiRNA (AI mRNA Sequence Design Platform); AiTEM (AI Small Molecule Formulation Design Platform); MTS-004 (PBA drug, first AI-enabled formulation drug to complete Phase III in China); MTS-105 (in vivo mRNA-encoded TCE solid tumor therapy); OpenCGT platform for cell and gene therapy
Unique value
World's first and only end-to-end AI nanodelivery platform (NanoForge) with the largest ionizable lipid library globally, proprietary lipid generation algorithms, and lipid language models — enabling targeted delivery to 8 key organs/tissues
Target customer
Global pharmaceutical companies, biotech firms, and medical research institutions seeking AI-powered drug formulation and delivery solutions
Industries served
Pharmaceuticals (small molecule, nucleic acid, biologics); Cell & Gene Therapy; Animal Health; Anti-aging therapeutics
Technology advantage
Proprietary AI foundation models + quantum chemistry/molecular dynamics simulations + high-throughput screening; world's largest ionizable lipid library (millions); only lipid de novo generation algorithm and lipid language model globally; first end-to-end LNP screening platform; AI+multi-scale simulation small molecule formulation platform; 224 patent applications filed, 52 granted
How they differentiate
Unlike competitors focused on AI drug discovery (molecule finding), METiS specializes in AI-driven drug DELIVERY (nanomaterials, LNPs, formulations) — the "last mile" problem in drug development. Only company with end-to-end AI nanodelivery platform covering lipid design, LNP formulation, mRNA optimization, and small molecule formulation. Incubated by XtalPi but operates in a complementary niche.
Main competitors
XtalPi (晶泰科技) - HKEX-listed AI drug discovery company, also METiS' incubator; Insilico Medicine - HKEX-listed AI drug discovery company; Standigm, Spark Biopharma
Key partnerships
Evopoint Biosciences (license agreement, Jan 2023); Voronoi (Pan-RAF inhibitor license, Sep 2022); Roche Accelerator (May 2022); AccurEdit Therapeutics (OpenCGT platform inaugural project for CRISPR gene-editing); 30+ global pharma and biotech partners
Notable customers
30+ global pharmaceutical and biotechnology partners including top global pharma companies, biotech firms, and medical research institutions; AccurEdit Therapeutics (CRISPR gene-editing collaboration); Evopoint Biosciences; Voronoi
Major milestones
2020: Founded, incubated by XtalPi; 2021: Launched with $86M Series A; 2022: $150M Series B; 2024: $100M Series C; 2025: Series D ¥400M; MTS-004 becomes China's first AI-enabled formulation drug to complete Phase III; Launched NanoForge (world's first AI nanodelivery platform); Selected as MIT Technology Review TR50; 2026-05-13: Listed on HKEX (7666.HK) as world's first AI drug delivery stock, raising $270M
Growth metrics
2025 revenue: ¥1.05B RMB ($145M) primarily from MTS-004 product collaboration upfront payment; IPO raised HK$2.1B ($270M); market cap ~HK$12.1B at IPO ($1.55B); 6,900x oversubscribed in Hong Kong public offering
Market positioning
First-mover and global leader in AI-driven nanodelivery; CB Insights ESP matrix "LEADER" for AI-driven drug formulation; world's first AI drug delivery stock on HKEX; positioned as the "Space X of pharma" for nano-rocket drug delivery
Geographic focus
China (primary R&D and commercialization base), US (METiS Therapeutics in Cambridge, MA), global pharma partnerships
Patents and IP
224 patent applications filed, 52 granted as of IPO date (May 2026)
About Dr. Chris Lai (赖才达)
Ex-McKinsey & Company Strategic Consultant; MIT PhD in Chemical Engineering (Novartis-MIT Center for Continuous Manufacturing); Founder of AquaFresco (water-tech startup); MIT Innovation Award in Clean Energy and Water Treatment
Official website: https://www.metistechbio.com